These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7823750)

  • 21. [Results of different programs of chemotherapy using rifampicin in patients with newly detected destructive pulmonary tuberculosis].
    Sodikov ES; Abrarov BA
    Probl Tuberk; 1986; (5):27-30. PubMed ID: 3526322
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
    Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
    Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection.
    Chaisson RE; Clermont HC; Holt EA; Cantave M; Johnson MP; Atkinson J; Davis H; Boulos R; Quinn TC; Halsey NA
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):1034-8. PubMed ID: 8887603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.
    Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.
    El-Sadr WM; Perlman DC; Denning E; Matts JP; Cohn DL
    Clin Infect Dis; 2001 Feb; 32(4):623-32. PubMed ID: 11181127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection.
    Jones BE; Otaya M; Antoniskis D; Sian S; Wang F; Mercado A; Davidson PT; Barnes PF
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1499-502. PubMed ID: 7952606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A short two-drug regimen prevents active TB.
    Torres G
    GMHC Treat Issues; 1998 Apr; 12(4):12. PubMed ID: 11365399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antitubercular chemotherapy].
    Jouveshomme S; Dautzenberg B
    Rev Mal Respir; 1997 Dec; 14 Suppl 5():S88-104. PubMed ID: 9496594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatal mycobacterial infection in a 32-year-old man with AIDS.
    Whitson BD; George RB
    Chest; 1994 Nov; 106(5):1577-9. PubMed ID: 7956422
    [No Abstract]   [Full Text] [Related]  

  • 30. [Short-course treatment of pulmonary tuberculosis: comparison with a classical standard regimen].
    Bouslama A; Hedhiri H; Marzouki M; Jerray M; Djenayah F
    Bull Int Union Tuberc; 1985; 60(1-2):29-30. PubMed ID: 4074969
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of severe open cavitary pulmonary tuberculosis with a combination of rifampicin and isoprodian (author's transl)].
    Pereira V
    Prax Pneumol; 1976 Sep; 30(9):584-7. PubMed ID: 967829
    [No Abstract]   [Full Text] [Related]  

  • 32. Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil.
    Croda J
    Rev Soc Bras Med Trop; 2015; 48(5):505-6. PubMed ID: 26516957
    [No Abstract]   [Full Text] [Related]  

  • 33. Empiric antituberculosis treatment: benefits for earlier diagnosis and treatment of tuberculosis.
    Anglaret X; Saba J; Perronne C; Lacassin F; Longuet P; Leport C; Vildé JL
    Tuber Lung Dis; 1994 Oct; 75(5):334-40. PubMed ID: 7841426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On treatment outcomes of patients with HIV and tuberculosis.
    Breen RA; Miller RF; Lipman MC
    Am J Respir Crit Care Med; 2008 Jan; 177(1):121; author reply 121-2. PubMed ID: 18096713
    [No Abstract]   [Full Text] [Related]  

  • 37. [Results of treatment of chronically infectious patients with rifampicin in various combinations and in various models].
    Górecki R; Stanek S
    Gruzlica; 1974 May; 42(5):411-6. PubMed ID: 4464229
    [No Abstract]   [Full Text] [Related]  

  • 38. Prolonged paradoxical reaction of tuberculosis in an HIV-infected patient after initiation of highly active antiretroviral therapy.
    Ramos A; Asensio A; Perales I; Montero MC; Martín T
    Eur J Clin Microbiol Infect Dis; 2003 Jun; 22(6):374-6. PubMed ID: 12774198
    [No Abstract]   [Full Text] [Related]  

  • 39. Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection.
    Yu WC; Lai ST; Chiu MC; Chau TN; Ng TK; Tam CM
    Int J Tuberc Lung Dis; 2006 Jul; 10(7):824-5. PubMed ID: 16850548
    [No Abstract]   [Full Text] [Related]  

  • 40. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Wada M
    Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.